Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX) in a research report sent to investors on Monday morning, Benzinga reports. The brokerage issued a buy rating and a $23.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on PTGX. BidaskClub raised Misonix from a buy rating to a strong-buy rating in a research note on Wednesday, July 3rd. ValuEngine raised VESTAS WIND SYS/ADR from a hold rating to a buy rating in a research note on Thursday, May 9th. Stifel Nicolaus raised Protagonist Therapeutics from a hold rating to a buy rating and raised their price objective for the company from $11.00 to $17.00 in a research note on Wednesday, May 8th. Finally, Zacks Investment Research lowered HEXO from a hold rating to a sell rating in a report on Wednesday, May 15th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $17.17.

Shares of Protagonist Therapeutics stock opened at $13.65 on Monday. The business has a 50-day simple moving average of $11.69. The stock has a market cap of $309.06 million, a P/E ratio of -7.84 and a beta of 1.88. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.02 and a current ratio of 5.02. Protagonist Therapeutics has a 1 year low of $5.49 and a 1 year high of $14.36.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.01. Protagonist Therapeutics had a negative return on equity of 40.78% and a negative net margin of 209.02%. The firm had revenue of $1.56 million during the quarter, compared to the consensus estimate of $2.50 million. Research analysts forecast that Protagonist Therapeutics will post -2.07 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Northern Trust Corp raised its position in Protagonist Therapeutics by 17.2% in the 4th quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock valued at $234,000 after purchasing an additional 5,084 shares during the last quarter. D. E. Shaw & Co. Inc. raised its position in Protagonist Therapeutics by 75.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock valued at $132,000 after purchasing an additional 8,450 shares during the last quarter. Bank of Montreal Can raised its position in Protagonist Therapeutics by 1,675.5% in the 1st quarter. Bank of Montreal Can now owns 11,026 shares of the company’s stock valued at $139,000 after purchasing an additional 10,405 shares during the last quarter. Bank of America Corp DE raised its position in Protagonist Therapeutics by 94.3% in the 4th quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock valued at $178,000 after purchasing an additional 12,819 shares during the last quarter. Finally, BlackRock Inc. raised its position in Protagonist Therapeutics by 8.8% in the 4th quarter. BlackRock Inc. now owns 260,548 shares of the company’s stock valued at $1,754,000 after purchasing an additional 21,126 shares during the last quarter. Hedge funds and other institutional investors own 64.40% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Read More: What is the balance sheet?

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.